edward deliv essenti line
rev essenti line number slightli
consensu ep adjust one-tim charg came
adjust jibe compani number gross margin
slightli less estim guidanc up higher end
 rang ep guidanc up tavr guidanc
upper end maintain construct stanc name
us tavi sale y/i as-report basi ou tavi rev
exclud stock order germani y/i fx impact
math indic procedures/day ou hospit
util basi us hospit util seem
japan tavr contribut unclear although compani commentari european
tavr procedur growth y/i edward track in-lin wit market
growth rate market share europ base check indic
spread ew other
contribut franc uk japan specif state
edward indic market share stabl
impact intermediate-risk approv label expans europ
still clear neither penetr rate inoper vs high-risk
updat cardiaq tmvr ce mark sapien groundwork laid
transsept approach tmvr state past note cardiaq
feedback europ continu quit weak
leg growth need kep tan eye centerra self-
expand motor valv premium harpoon
medic chordal repair system tmvr low-risk avr launch
view compani real growth opportun howev caution
warrant rememb stock least sum part basi
alreadi reflect sale multipl tavr portion busi
unless tmvr come on-line strong result fundament imposs
get bullish name sure argument appli crazi multipl
order see come biggest price target count us
introduc number pt get adjust accordingli
ew report number us tavi rev gaap tavi sale non-gaap tavi sale
royalti sale return reserv vs estim consensu underli
tavi sale y/i as-report basi ou tavi rev came y/i vs
estim as-report basi remind ou sale includ stock order germani
hospit bought inventori fear injunct due litig
inventori purchas drawn ou sale includ contribut inventori purchas
although abl glean exact amount fx seem decent compon growth given
dollar depreci vs euro last year compani indic bp ou contribut
came fx world-wide tavr sale y/i compani indic double-
digit growth across region asp stabl across region procedur growth roughli
line market growth ou compani saw strong recoveri franc rememb growth franc
stymi quota cap tavr growth japan also strong although specif japan
franc provid compani indic japan growth continu driven high-risk patient
europ overal market growth rang interestingli enough compani seem
suggest share europ stabil becom interest thing watch progress
especi lotu valv launch remind price premium
europ compani gear gain ce mark centerra self-expand system price
premium launch later last field check indic europ share
roughli rang edward other respect commentari aggreg continu
blurri extent intermediate-risk market penetr extent contribut guidanc
number procedures/day saw sequenti step edward ad new center
bring total slightli center math indic roughli sapien
sold quarter
figur order actual vs estim mm tavi procedures/busi day stratifi geographi
page
thing mention note
compani indic stabl price europ addit price
premium compar europ
growth skew toward new lower volum center net center ad
quarter
adopt saw step chang rel compani clarifi exact
contribut intermediate-risk especi one assum sequenti step-up
procedures/day predominantli due bolu intermediate-risk patient come on-line
referr channel compani tri tamp wild extrapol current util
quarter indic quarter ebb flow long-term view tavr sale
remain appropri bogey
japan tavr contribut quarter specif state
rememb exit compani indic sapien present site
impli exit number site around remind number
high-volum cath lab around medium volum center around low-volum
center around henc theoret tavr usag alreadi move lower-volum
segment would interest note increment new site ad per quarter slow
even
commentari call indict europ tavi procedur growth rang
edward growth europ track market growth straight quarter confess
reconcil edward commentari procedur growth vs price vs market share europ
ou guesstim roughli center activ involv tavi procedur rememb as-report
y/i growth europ specif state
guesstim approx sapien sold approx hospit ou impli rate approx
 sale rate assum center seem around
sequenti basi
interest note pure surgic aortic valv basi util rate base
field check usual around henc metric tavi penetr
util come rather quickli bear mind util rate would also need
ad edward number would need compar aggreg util rate
savr state otherwis cannib intermedi risk patient tavi occur full swing post-
sapien launch expect growth rate skyrocket even
surgic heart valv base report number y/i note past
quarterli run rate surgic heart valv approx run rate world-wide
math indic segment approx sequenti essenc surgic heart valv
trend downward past year despit higher like valv
magna eas mitral aortic intuiti elit howev talli number indic best case
loss roughli range/quart simultan world-wide tavr
sale sapien skyrocket current run rate approx exclud
germani stock order approx surgic heart valv state otherwis averag
surgic heart valv around impli world-wide unit sale approx
sapien approx sale exit world-wide basi differ
price tavi surgic valv combin continu cannib surgic valv
provid answer chang gross margin mix strateg outlook
europ field check indic case edward continu
technic off-label intermedi low risk surgic heart valv patient siphon
tavi mathemat singl patient siphon away off-label use surgic heart valv tavr
yield top-lin benefit ebit margin benefit approx bp one see
push cannib question though price sustain long
impact guidanc call increas tavr across differ patient group therefor make
 faster growth market histor howev contribut uk
page
figur order tavi sale geographi mm segment rev mm
page
minim sale cardioband recogn qtr compani provid cardioband revenu
guidanc signific step-up remind compani state earlier
cardioband contribut would still clear besid ip acquisit
rational valtech deal edward indic look simplifi patient protocol
make product enhanc cardioband make adapt tricuspid use also rememb
call compani highlight creation separ cardioband mitral sale team
ground hire requisit folk take longer expect lead slower ramp rate
origin assess cardioband remainswhil edward probabl look gather ip
mitral repair space maintain cardioband procedur tricki one adapt
interestingli virtual mention cardiaq tmvr program statu ce studi
transap approach compani lay groundwork move sapien
platform via transsept rout check europ continu indic cardiaq program
essenti troubl understand key member origin cardiaq team
enrol low-risk trial complet data present expect
earli tavr trial enrol start rememb earli tavr asymptomat sever patient
compani expect ce mark harpoon chordal repair devic
centerra ce market ce subsequ europ launch premium self-expand system wait
late introduct sapien ultra system valv higher skirt
label differ countri bring late earli
guidanc updat follow
world-wide tavi sale higher end guidanc critic segment guidanc
 surgic heart valv guidanc toward higher end previou guidanc
overal revenu guidanc higher end
gross margin expect rang ep note ep estim
jibe compani guidanc given adjust make ipr litig charg etc
 sale sg sale
tax rate sale earlier guidanc due impact new acctg
impact stock option expens new tax law ou earn repatri
estim introduc revenu sale ep
figur approx util metric world-wide basi
page
maintain outperform rate continu posit view fundament view remain
strateg asset want long-term level upsid far downsid
introduc number pt tweak still use rational approx tavi sale
non-tavi biz tmvr piec till viabil mitral program establish hard
time justifi signific increas pt
page
statement oper
number mm round
good sold
sg
page
edward lifesci world leader surgic heart valv sapien platform transcathet heart valv
also current posit world
pt deriv use sum part methodolog
risk achiev price target
suraj kalia certifi view express report accur reflect person view
subject compani secur part compens directli
indirectli relat specif recommend view express report
